研究单位：[1]Kawin Technology Share-holding Co., Ltd.[2]First Hospital of Jilin Univerisity[3]Capital Medical University Affiliated Beijing Youyi Hospital[4]Huazhong University of Science and Technology Affiliated Tongji Hospital
This study aimed to confirm efficacy and safety of KW-136, an investigational anti-hepatitis C virus (HCV) drug, combined with sofosbuvir for treatment of naive and experienced adults chronically infected with HCV. Three hundred and sixty (360) non-cirrhotic and cirrhotic subjects were medicated with KW-136 60 mg daily and sofosbuvir 400 mg daily. The treatment course lasted 12 successive weeks; thereafter all the study participants entered into a 12-week treatment-free follow-up period and an additional 12-week extension treatment-free follow-up period.
